SONG Qi-bin, WANG Qi, HU Wei-guo. Association of XPD Lys751Gln with Clinical Outcome of Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis[J]. Journal of Evidence-Based Medicine, 2013, 13(4): 236-241. DOI: 10.3969/j.issn.1671-5144.2013.04.013
    Citation: SONG Qi-bin, WANG Qi, HU Wei-guo. Association of XPD Lys751Gln with Clinical Outcome of Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis[J]. Journal of Evidence-Based Medicine, 2013, 13(4): 236-241. DOI: 10.3969/j.issn.1671-5144.2013.04.013

    Association of XPD Lys751Gln with Clinical Outcome of Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis

    • Objective To evaluate the association between XPD Lys751Gln and the clinical outcome of platinum-based chemotherapy in advanced NSCLC and guide the clinical medication and individualized treatment. Methods A meta-analysis was used to analyze the association between XPD Lys751Gln and the clinical outcome in advanced NSCLC patients treated with platinum-based chemotherapy. Results A total of 15 case-control studies were included in the meta-analysis. The result showed no associations between XPD Lys751Gln and the clinical outcome of platinum-based chemotherapy in advanced NSCLC patients. The pooled OR values for Lys/Gln+Gln/Gln compared with Lys/Lys was 1.26(95%CI 0.96~1.66). The pooled HR for death in patients with Lys/Gln+Gln/Gln was 1.06(95%CI 0.81~1.37). In the subgroup analysis by ethnicity, no statistically differences were found between XPD Lys751Gln and survival in advanced NSCLC patients treated with platinum-based chemotheray. Conclusion The result of meta-analysis suggests that no association between XPD Lys751Gln and the clinical outcome of platinum-based chemotherapy in advanced NSCLC. Further studies are needed to validate the conclusion.
    • loading

    Catalog

      Turn off MathJax
      Article Contents

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return